Which company develops and produces capmatinib?

Capmatinib (Capmatinib) is developed and produced by the global pharmaceutical giant Novartis (Novartis). Novartis, headquartered in Basel, Switzerland, is one of the world's leading biopharmaceutical companies, focused on providing innovative treatment solutions to patients around the world. Novartis is committed to conducting research in multiple therapeutic areas, including oncology, neuroscience, ophthalmology, cardiovascular disease and more.

Novartis was founded in1996. Through multiple acquisitions and innovations, it has occupied an important position in the global biopharmaceutical industry. Many of the company's drugs are widely used in the treatment of various diseases, especially in the field of oncology. Novartis' drugs occupy a place in the global market. Novartis drives progress in oncology treatments through scientific innovation and continued investment.

Capmatinib is a targeted anti-cancer drug developed by Novartis. It is mainly used to treat MET gene-driven non-small cell lung cancer (NSCLC). This drug can effectively inhibit the growth of tumors by inhibiting the abnormal activation of MET receptors. Capmatinib has shown significant efficacy in clinical trials, especially in lung cancer patients with MET gene mutations or amplifications. During the development process of capmatinib, Novartis conducted multiple clinical trials to verify its safety and effectiveness.

Capmatinib was approved by the USFDA in 2020 for the treatment of non-small cell lung cancer driven by MET gene mutations. The drug was subsequently approved in Europe and elsewhere. As a precision treatment drug, capmatinib provides a new treatment option for patients with non-small cell lung cancer with MET gene mutations. Its launch marks an important breakthrough for Novartis in the field of oncology.

As one of the world's largest pharmaceutical companies, Novartis launches innovative medicines in multiple markets around the world, especially in the field of oncology. The successful development and launch of capmatinib is an important achievement for Novartis in the field of targeted cancer treatment. By continuously promoting drug research and development and innovation, Novartis hopes to provide patients with more effective treatment options and improve their quality of life.

xa0

Reference materials

Official website of Novartis: https://www.novartis.com